Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
18 Julio 2024 - 3:05PM
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced
that it will report second quarter 2024 financial results on
Thursday, August 8, 2024 after the market closes. Company
management will host a conference call at 4:30 p.m. ET that day to
discuss financial results and provide a business update.
Conference Call & Webcast
Thursday, August
8th @ 4:30 PM
ET
Domestic: |
1-800-267-6316 |
International: |
1-203-518-9783 |
Conference ID: |
CRNXQ2 |
|
|
Participants can use the dial-in numbers above OR access the
call via live webcast on the Events section of the Crinetics
website. To ensure a timely connection, it is recommended that
participants dial-in or register at least 15 minutes prior to
scheduled start of the call.
The webcast will be archived on the Investor Relations sections
of www.crinetics.com.
About Crinetics
Pharmaceuticals Crinetics Pharmaceuticals is a
clinical stage pharmaceutical company focused on the discovery,
development, and commercialization of novel therapeutics for
endocrine diseases and endocrine-related tumors. Paltusotine,
an investigational, first-in-class, oral somatostatin receptor type
2 (SST2) agonist, is in Phase 3 clinical development for acromegaly
and Phase 2 clinical development for carcinoid syndrome associated
with neuroendocrine tumors. Crinetics is also developing atumelnant
(CRN04894), an investigational, first-in-class, oral ACTH
antagonist, that is currently completing Phase 2 clinical studies
for the treatment of congenital adrenal hyperplasia and
ACTH-dependent Cushing’s syndrome. All of the Company’s drug
candidates are orally delivered, small molecule new chemical
entities resulting from in-house drug discovery efforts, including
additional discovery programs addressing a variety of endocrine
conditions such as hyperparathyroidism, polycystic kidney disease,
Graves’ disease, thyroid eye disease, diabetes and obesity.
Contact:Gayathri DiwakarHead of Investor
Relationsgdiwakar@crinetics.com(858) 345-6340
Media:Natalie BadilloHead of Corporate
Communicationsnbadillo@crinetics.com (858) 345-6075
Source: Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals (NASDAQ:CRNX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Crinetics Pharmaceuticals (NASDAQ:CRNX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024